A replication-competent adenovirus was successfully designed to replicate conditionally in PSA-positive and PSMA-positive prostate cancer cells, and this construct would be expected to have potent antitumor effects and deserves more extensive investigation.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and current therapeutics provide limited benefits to patients. Desmoplasia and the highly immunosuppressive tumor microenvironment (TME) play a huge role in PDAC being elusive to current therapeutics. Here, we strategically selected four transge...
Brett L. Roach, Mizuho Sato-Dahlman, Kari L. Jacobsen et al.· Molecular Cancer Therapeutic...· 0 citations
Oncolytic viruses have emerged as a promising strategy in cancer immunotherapy and have been applied to the treatment of various tumors. We previously demonstrated that oncolytic adenoviruses engineered expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) could induce apoptosis in tumor cells and...
Wen-Mo Liu, Li-Ying Wang, Xu-Pu Wang et al.· Molecular Cancer Therapeutic...· 0 citations
The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient
in vivo
delivery of tumor antigens to dendritic cells (DCs), the key regulators of T-cell immunity.
To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through ra...
Xin Wei, Xiang Li, Li-Xia Qi et al.· Frontiers in Immunology· 0 citations
Direct intratumoral administration of immune-stimulating agents can generate systemic immunity following a tumor-localized immune response. Interleukin 12 (IL-12) activates T cells and reverses immunosuppression, generating a localized patient-antigen-specific immune response. Changes in the tumor microenvironment in r...
L. Heller, Julie Singh, Jody C. Synowiec et al.· Gene Therapy· 0 citations
C57BL/6 mice in which a truncated variant of human EGFR (hEGFRt), lacking the ligand binding domain and cytoplasmic domain, is expressed from the CAG regulatory elements comprised of the CMV enhancer, β-actin promoter, and β-globin poly-adenylation signals are developed.
Theresa Barberi, Rahila Khuroo, Alan D. Friedman· PLoS ONE· 0 citations
Oncolytic Virotherapy (OVT) is an emerging area of cancer immunotherapy
that has shown promise as a therapeutic agent, leveraging genetically engineered replication-
competent viruses that kill cancer cells without harming normal cells. HSV-1 (T-VEC),
vaccinia, and adenoviruses. Immuno-Oncology Oncol Ther 2017; Mon...
Indu Arora, Shalu Attar, Priyanka Bhardwaj et al.· Clinical Cancer Drugs· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
